secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001213900-25-014154
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed reports Q2 net loss $2.6M, cash $3.5M; board accepts director resignation
-------------------------------------------------------------------------------

- Net loss of $2.6M for Q2 FY2025 (Dec 31, 2024), vs $1.5M loss a year ago; GAAP loss per share $3.64.
- Cash and equivalents $3.5M as of Dec 31, 2024; company raised $2.9M in Jan 2025, enough through Q2 2025.
- BayMedica revenue $1.1M (-10% YoY); BayMedica achieved net income of $0.23M (189% improvement).
- Board accepted resignation of director Janet Grove effective Feb 10, 2025, following withheld votes at Dec 2024 AGM.
- R&D expenses $1M (up from $0.6M); pipeline updates: INM-901 (Alzheimer's) and INM-089 (dry AMD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/0001213900-25-014154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025014154/ea0231142-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-014154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer